Telehealth is the channel that built the compounded GLP-1 economy. Hims & Hers, Ro, LifeMD, Eucalyptus, MedVi, JustCare Health, BoomRx, and similar programs scaled to billions in revenue on top of FDA-declared shortages of semaglutide and tirzepatide between 2022 and 2024.
The post-shortage rules have forced re-routing. Some programs pivoted to additive formulations to stay inside 503A patient-specific compounding rules; others moved into sermorelin, peptide stacking, and broader peptide therapy. Most have lobbied around the Outsourcing Facilities Association litigation and the April 30, 2026 FDA proposal to exclude branded GLP-1s from the 503B bulks list. The University of Colorado secret-shopper study quantified the gap — 65–69 of 74 weight-loss clinics still sold compounded GLP-1s as of April 2026.
Stories here cover platform-level pivots, partnership news, and the regulatory exposure.
Hims & Hers announced April 23 a strategic expansion of its U.S. weight loss platform, adding licensed-provider prescriptions for Eli Lilly's Zepbound vials, Zepbound KwikPen, and Foundayo. Prescriptions are fulfilled through LillyDirect pharmacy, completing a dual-supplier arrangement after last month's Novo Nordisk Wegovy collaboration. Shares jumped roughly 7% on the announcement as investors digested the company's pivot from compounded GLP-1s toward branded distribution.
Telehealth rival Hims & Hers Health shares slid 6% April 21-22 after Amazon's One Medical launched a comprehensive GLP-1 weight management program offering Wegovy and Foundayo starting at $25/month with insurance or $149/month cash-pay for oral options. The move positions Amazon against established telehealth obesity care providers (Hims, Ro, LifeMD, Noom) as the compounded-GLP-1 era winds down.
CNBC analysis frames Hims & Hers Health as the biggest direct-to-consumer beneficiary of the FDA's July PCAC meeting. Hims acquired a California peptide manufacturing facility in 2025 and can convert its GLP-1 compounding infrastructure to peptide production. The stock closed up 11.07% on April 16 after the FDA announcement; Bank of America raised its price target from $21 to $25, citing the platform's conversion potential.
Hims & Hers Health Inc. jumped as much as 12% after the FDA's advisory panel announcement, with investors betting the telehealth company will benefit from expanded legal access to compounded peptide therapies. RFK Jr. stated on X that this action would 'immediately begin shifting demand away from the black market.'
MEDVi, a $1.8B AI-powered telehealth company with just two full-time employees, received an FDA warning letter in February 2026 for misbranding compounded semaglutide and tirzepatide.
The FDA issued warning letters to 30 telehealth firms for false or misleading claims about compounded GLP-1 weight-loss products, signaling a major crackdown on illegal online marketing.